GCIA
ESPR

Gabelli & Co Investment Advisers’s Esperion Therapeutics ESPR Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.32M Buy
+2,315,900
New +$6.48M 1.06% 22

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $15.7B AUM 36.4% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Gabelli & Co Investment Advisers's ESPR Position: Q2 2026 in Review

Gabelli & Co Investment Advisers opened a new position in Esperion Therapeutics (ESPR) in Q2 2026: 2,315,900 shares worth $7.32M. The stake represents 1.06% of the portfolio and ranks #22 among its holdings.

130 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Gabelli & Co Investment Advisers held 2,315,900 shares of Esperion Therapeutics worth $7.32M as of Q2 2026.
  • Esperion Therapeutics was a new Gabelli & Co Investment Advisers position in Q2 2026.
  • Esperion Therapeutics made up 1.06% of Gabelli & Co Investment Advisers's portfolio in Q2 2026, its #22 holding.
  • 130 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Gabelli & Co Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.